JournalTOCs

Publisher: Edwiser International (Total: 4 journals) [Sort by number of followers]

Showing 1 - 4 of 4 Journals sorted alphabetically
	Intl. J. of Biomedical Investigation
	Intl. J. of General Medicine & Surgery
	Intl. J. of Pharmaceutics & Pharmacology
	Medical Case Reports J.

Most Followed Journals

Top Publishers

Top Subjects

Similar Journals

International Journal of Pharmaceutics & Pharmacology
Number of Followers: 0

This is an Open Access Journal

Open Access journal
ISSN (Online) 2581-3080
Published by Edwiser International

[4 journals]

- Authors: Frank-AM-Ari-H-Jussi-K-et-al-
  Abstract: {Objective: Despite the increased patronage of herbal medicinal products (HMP), they remain poorly regulated in Ghana and their efficacy and safety data is seldom adequate. The objective of the present study is to provide insight into concerns regarding post-market HMP safety and efficacy from the perspectives of users in Kumasi, Ghana. Methods: Thirty-seven randomly selected HMP consumers in Kumasi, were interviewed using semi-structured questionnaire. Non-users of HMPs and users less than 18 years were excluded from the study. Mixed method sampling method was used for the study.Results: HMPs were reported to be gentle and safer than orthodox medicines by informants. Only 19% of informants voluntarily reported HMP use to their general practitioner. Informants (94.6%) experienced minimal effects, whiles (5.4%) experienced moderately severe adverse effects. Conclusion: It was observed from the study that some HMPs are however non-effective and harmful. We would suggest that HMP users should exercise caution with regards to where to buy and when using HM. Shyness and the feeling of being condemned by the physician were identified to be the possible causes of the communication barrier between the physicians and the HM users. We recommend physicians to initiate discussion on this topic during consultations and guide users on safe use of these HMPs.}
  PubDate: 28-Oct-2019
Pharmacovigilance-System-in-Bangladesh-A-Regulatory-Perspective
- Authors: Mohammad-Wasif-Khan
  Abstract: {National pharmacovigilance centre of a country coordinates the overall activity of pharmacovigilance in collaboration with international regulatory authorities like WHO-UMC etc. The pharmacovigilance system establishment in public health has encouraging impact on health-care system improvement. To ensure the safety of medication system in Bangladesh, DGDA is leading from the front. In 2013, the Ministry of Health and Family Welfare, Bangladesh declared the DGDA as the National Pharmacovigilance Centre for Bangladesh, with the ADRM cell overseeing the centres activities. The MOHFW also set up the independent ADR Advisory Committee to work in conjunction with the ADRM cell to provide technical guidance for implementing PV activities, evaluating ADE reports, and recommending regulatory decisions and actions to ensure medicine safety. The DGDA has developed guidelines and strategies to implement PV activities across the country in cooperation with all stakeholders. The salient features of current PV regulations in Bangladesh are: An appropriate PV system is in place within the company to conduct post-marketing surveillance activities; Suspected adverse reactions to drugs must be reported using the electronic version of the reporting form available in the fillable pdf on DGDA website and submitted to the ADRM cell; Submit PSURs and company-sponsored post-registration study reports to the ADRM cell on a quarterly basis; Respond promptly and fully to requests for risk/benefit information from the ADRM cell.}
  PubDate: 04-Aug-2019
- Authors: Jahangir-MA-and-Rao-AP
  Abstract: {Blood Cancer is one of the leading causes of death globally. As per National Foundation for Cancer Research 1.2 million people in the U.S alone is living with blood cancer. According to the statistical data provided by Leukemia & Lymphoma Society every 3 minutes a new person is diagnosed with some type of blood cancer. Adding to the complexity of the disease there is no accurate survival data available. Generally, blood cancers are of three distinct types affecting the leucocyte cells (Leukemia), lymphocytes (Lymphoma) and plasma cells like B lymphocytes (Myeloma). These are further sub-classified according to severity and effected cells. Recent advancements in diagnostic technique have significantly increased the survival rate. }
  PubDate: 04-Aug-2019